10 Best NASDAQ Stocks Under $50 to Buy

3. UroGen Pharma Ltd. (NASDAQ:URGN)

Upside potential as of June 16, 2025: 139.75%

On Monday, analysts at H.C. Wainwright significantly raised the rating for UroGen Pharma Ltd. (NASDAQ:URGN) to Buy from Neutral, with a price target of $50.00. This revision was after Thursday’s regulatory approval of Zusduri, priced at $21,500 per dose.

With the stock price increasing by over 100% in the past five days and the potential to rise even further, investors have little to worry about. UroGen Pharma Ltd. (NASDAQ:URGN), exhibiting an impressive gross margin of around 90%, is set for a product launch aimed at non-muscle invasive bladder cancer, which affects as many as 59,000 patients annually in the U.S. alone. By 2026, the treatment is anticipated to achieve expected performance, generating $1 billion in sales.

While clarity around the approval path for UGN-103 is sought by the analysts, the management believes potential changes to the clinical trial strategy insignificantly impact its financial outlook. Having said that, UGN-103 is crucial for advancing the giant’s franchise exclusivity beyond early 2031.

UroGen Pharma Ltd. (NASDAQ:URGN) is a clinical-stage biopharmaceutical company founded in 2004. This New Jersey-based company develops and markets treatments for urothelial and specialty cancers. The company’s core offerings include RTGel and Jelmyto, with UGN-102, UGN-103, and UGN-104 being the lead product candidates.

2. Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Upside potential as of June 16, 2025: 316.74%

Analysts at H.C. Wainwright have reaffirmed a Buy rating on Intellia Therapeutics, Inc. (NASDAQ:NTLA) while maintaining a price target of $30.00. This whopping 237% upside from the current price followed the company’s positive three-year data for its hereditary angioedema (HAE) treatment presentation at the European Academy of Allergy and Clinical Immunology meeting.

What emerged from the findings was truly impressive. The Phase 1 trial data demonstrated that a single dose of lonvoguran ziclumeran (lonvo-z, or NTLA-2002) resulted in a 98% mean reduction in monthly HAE attack rates in all 10 patients evaluated.

The treatment maintained effectiveness throughout the three years, with sustained effects noted across the study. These results are in sync with the nature of gene editing, which is designed to produce lasting changes to the genome.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a Massachusetts-headquartered clinical-stage gene editing company. The giant develops curative genome editing treatments. In collaboration with AvenCell Therapeutics, Inc., the company aims to create innovative therapies for a range of diseases.